Publicaciones en colaboración con investigadoras/es de Hospital Universitario de Donostia (169)

2024

  1. Effectiveness of Helicobacter pylori Treatments According to Antibiotic Resistance

    American Journal of Gastroenterology, Vol. 119, Núm. 4, pp. 646-654

  2. Human Leukocyte Antigen Signatures as Pathophysiological Discriminants of Microscopic Colitis Subtypes

    Journal of Crohn's and Colitis, Vol. 18, Núm. 3, pp. 349-359

  3. Initial Management of Intra-abdominal Abscesses and Preventive Strategies for Abscess Recurrence in Penetrating Crohn's Disease: A National, Multicentre Study Based on ENEIDA Registry

    Journal of Crohn's & colitis, Vol. 18, Núm. 4, pp. 578-588

  4. Use of multi-gene panels in patients at high risk of hereditary digestive cancer: position statement of AEG, SEOM, AEGH and IMPaCT-GENÓMICA consortium

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 3, pp. 293-318

  5. m6A Methylated Long Noncoding RNA LOC339803 Regulates Intestinal Inflammatory Response

    Advanced Science, Vol. 11, Núm. 13

2023

  1. A Novel Approach on the Use of Samples from Faecal Occult Blood Screening Kits for Metabolomics Analysis: Application in Colorectal Cancer Population

    Metabolites, Vol. 13, Núm. 3

  2. A second update on mapping the human genetic architecture of COVID-19

    Nature

  3. A3907, a systemic ASBT inhibitor, improves cholestasis in mice by multiorgan activity and shows translational relevance to humans

    Hepatology (Baltimore, Md.), Vol. 78, Núm. 3, pp. 709-726

  4. BMPR2 as a Novel Predisposition Gene for Hereditary Colorectal Polyposis

    Gastroenterology, Vol. 165, Núm. 1, pp. 162-172.e5

  5. Empirical rescue treatment of Helicobacter pylori infection in third and subsequent lines: 8-year experience in 2144 patients from the European Registry on H. pylori management (Hp-EuReg)

    Gut, Vol. 72, Núm. 6, pp. 1054-1072

  6. Erratum to: Mapping the human genetic architecture of COVID-19 (Nature, (2021), 600, 7889, (472-477), 10.1038/s41586-021-03767-x)

    Nature

  7. Inhibition of YTHDF1 by salvianolic acid overcomes gluten-induced intestinal inflammation

    Gut

  8. Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma

    Journal of Hepatology, Vol. 79, Núm. 1, pp. 93-108

  9. Long-Term Outcomes of Biological Therapy in Crohn's Disease Complicated with Internal Fistulizing Disease: BIOSCOPE Study from GETECCU

    American Journal of Gastroenterology, Vol. 118, Núm. 6, pp. 1036-1046

  10. Natural history of liver disease in a large international cohort of children with Alagille syndrome: Results from the GALA study

    Hepatology, Vol. 77, Núm. 2, pp. 512-529

  11. Prevalence and description of disorders of gut–brain interaction in Spain according to the results of the Rome Foundation Global Epidemiology Study

    Neurogastroenterology and Motility, Vol. 35, Núm. 6

  12. Real-world outcomes of switching from adalimumab originator to adalimumab biosimilar in patients with inflammatory bowel disease: The ADA-SWITCH study

    Alimentary Pharmacology and Therapeutics, Vol. 58, Núm. 1, pp. 60-70

  13. Screening uptake of colonoscopy versus fecal immunochemical testing in first-degree relatives of patients with non-syndromic colorectal cancer: A multicenter, open-label, parallel-group, randomized trial (ParCoFit study)

    PLoS Medicine, Vol. 20, Núm. 10

  14. Serum DNA methylome of the colorectal cancer serrated pathway enables non-invasive detection

    Molecular Oncology

  15. Serum methylation of GALNT9, UPF3A, WARS, and LDB2 as noninvasive biomarkers for the early detection of colorectal cancer and advanced adenomas

    Clinical Epigenetics, Vol. 15, Núm. 1